CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on February 20, 2008
Clinical Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.2215/CJN.00480107
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.00480107v1
3/2/337    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macdougall, I. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdougall, I. C.

Received January 26, 2007
Accepted on December 11, 2007

ORIGINAL ARTICLES

C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis: Results of a Randomized Clinical Trial

Iain C. Macdougall *1, Rowan Walker {dagger}, Robert Provenzano {ddagger}, Fernando de Alvaro {sect}, Harold R. Locay ||, Paul C. Nader , Francesco Locatelli **, Frank C. Dougherty {dagger}{dagger}, Ulrich Beyer {dagger}{dagger}, and on behalf of the ARCTOS study investigators

*Department of Renal Medicine, King’s College Hospital, London, United Kingdom; {dagger}Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia; {ddagger}Division of Nephrology, St. John Hospital and Medical Center, Detroit, Michigan; {sect}Nephrology Department, Hospital Universitario La Paz, Madrid, Spain; ||Discovery Medical Research Group, Ocala, Florida; ¶Capital Nephrology Associates of Texas Ltd., Austin, Texas; **Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy; and {dagger}{dagger}F. Hoffmann-La Roche Ltd., Basel, Switzerland


1 To whom correspondence should be addressed. E-mail: iain.macdougall{at}kch.nhs.uk.


   Abstract

Background and objectives: This study examined the efficacy of C.E.R.A., a continuous erythropoietin receptor activator, for correcting anemia in patients who had chronic kidney disease (CKD) and were not on dialysis.

Design, setting, participants, & measurements: In this open-label, randomized, parallel-group, Phase III study, 324 adult patients with CKD not on dialysis nor receiving treatment with erythropoiesis-stimulating agents (ESAs) were randomly assigned (1:1) to receive subcutaneous C.E.R.A. once every 2 wk or darbepoetin alfa once weekly during an 18-wk correction period and a 10-wk evaluation period. Thereafter, patients receiving C.E.R.A. were randomly assigned to C.E.R.A. once every 2 wk or once monthly, and patients receiving darbepoetin alfa could receive darbepoetin alfa once weekly or once every 2 wk for a 24-wk extension period. Dosage was adjusted to achieve a hemoglobin (Hb) response and to maintain Hb ±1 g/dl of the response level and 11 to 13 g/dl. Primary end points were Hb response rate during correction and evaluation and change in Hb concentration between baseline and evaluation.

Results: Hb response rates were 97.5% for C.E.R.A. and 96.3% for darbepoetin alfa. Adjusted mean changes in Hb from baseline to evaluation were 2.15 g/dl (C.E.R.A.) and 2.00 g/dl (darbepoetin alfa). Analysis showed that C.E.R.A. once every 2 wk was as effective as darbepoetin alfa once weekly for correcting anemia. Hb levels remained stable in all groups during the extension period. C.E.R.A. and darbepoetin alfa were well tolerated.

Conclusions: Subcutaneous C.E.R.A. once every 2 wk corrects anemia in ESA–naive patients who are not on dialysis.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Society of Nephrology.